Paragon Care Limited (ASX:PGC)

Australia flag Australia · Delayed Price · Currency is AUD
0.1550
-0.0050 (-3.13%)
Apr 29, 2026, 4:10 PM AEST
Market Cap264.85M -58.4%
Revenue (ttm)3.67B +8.5%
Net Income-13.93M
EPS-0.01
Shares Out1.66B
PE Ration/a
Forward PE9.64
Dividendn/a
Ex-Dividend Daten/a
Volume1,492,404
Average Volume520,817
Open0.1600
Previous Close0.1600
Day's Range0.1550 - 0.1600
52-Week Range0.1550 - 0.4500
Beta1.42
RSI38.83
Earnings DateMay 26, 2026

About Paragon Care

Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, b... [Read more]

Sector Healthcare
Founded 2005
Employees 550
Stock Exchange Australian Securities Exchange
Ticker Symbol PGC
Full Company Profile

Financial Performance

In fiscal year 2025, Paragon Care's revenue was 3.61 billion, an increase of 21.68% compared to the previous year's 2.97 billion. Earnings were 20.57 million, an increase of 151.52%.

Financial Statements

News

Paragon Care Ltd (ASX:PGC) (Q1 2026) Earnings Call Highlights: Resilient Performance Amidst ...

Paragon Care Ltd (ASX:PGC) (Q1 2026) Earnings Call Highlights: Resilient Performance Amidst Challenges

2 months ago - GuruFocus

Half Year 2026 Paragon Care Ltd Earnings Call Transcript

Half Year 2026 Paragon Care Ltd Earnings Call Transcript

2 months ago - GuruFocus

Paragon Care Earnings Call Transcript: H1 2026

Underlying revenue reached AUD 1.9 billion with EBITDA of AUD 49 million, while statutory results were impacted by a full provision for Infinity Group debt. Strong organic growth in Asia and contract logistics offset challenges, and full-year guidance is reaffirmed.

2 months ago - Transcripts

Paragon Care Earnings Call Transcript: H2 2025

Revenue grew 8.3% to $3.6 billion and underlying EBITDA rose 3% to $95.2 million, driven by strong Asia-Pacific and pharmacy performance. Integration synergies of $5 million were achieved, with $12 million targeted for FY 2026, and a $400 million refinancing improved capital flexibility.

8 months ago - Transcripts

Paragon Care Earnings Call Transcript: H2 2024

The merger created a diversified healthcare business with FY24 pro forma revenue of AUD 3.3 billion and EBITDA of AUD 91 million. Integration is progressing, with cost synergies and organic growth prioritized, despite challenges in the Australian market.

1 year ago - Transcripts